Xiaoqing Li

Shenzhen, 518035, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Clinical outcomes and molecular features of CEBPA-mutated MPAL: a multi-center case series.

Clinical outcomes and molecular features of CEBPA-mutated MPAL: a multi-center case series.

Journal: Experimental hematology & oncology

Published: May 31, 2026

A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma.

A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: April 24, 2026

A real-world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation.

A real-world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation.

Journal: British journal of haematology

Published: February 13, 2026

Efficacy and Safety of CLAG-Based Sequential Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Non-Remission Relapsed or Refractory Acute Leukemia.

Efficacy and Safety of CLAG-Based Sequential Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Non-Remission Relapsed or Refractory Acute Leukemia.

Journal: Blood and lymphatic cancer : targets and therapy

Published: February 06, 2026

DCANet: Disentanglement and Category-Aware Aggregation for Medical Image Segmentation.

DCANet: Disentanglement and Category-Aware Aggregation for Medical Image Segmentation.

Journal: Sensors (Basel, Switzerland)

Published: January 21, 2026

Comprehensive investigation of cuproptosis-related genes in clinical features, biological characteristics, and immune microenvironment in B-cell Non-Hodgkin lymphoma.

Comprehensive investigation of cuproptosis-related genes in clinical features, biological characteristics, and immune microenvironment in B-cell Non-Hodgkin lymphoma.

Journal: Journal of translational internal medicine

Published: October 31, 2025

Late and Durable Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma.

Late and Durable Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma.

Journal: International journal of cancer

Published: September 01, 2025

Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study.

Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study.

Journal: Cancer medicine

Published: June 18, 2024

Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma.

Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma.

Journal: Leukemia

Published: May 26, 2024

Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing.

Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 21, 2024

Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma.

Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma.

Journal: Frontiers in genetics

Published: November 15, 2021

Mechanisms of failure of chimeric antigen receptor T-cell therapy.

Mechanisms of failure of chimeric antigen receptor T-cell therapy.

Journal: Current opinion in hematology

Published: October 03, 2019

Showing 1-12 of 15

Last Updated: 09/26/2026